146 related articles for article (PubMed ID: 16787326)
21. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
22. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
23. Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models.
Braidwood L; Learmonth K; Graham A; Conner J
J Hepatocell Carcinoma; 2014; 1():149-61. PubMed ID: 27508184
[TBL] [Abstract][Full Text] [Related]
24. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
Miao L; Fraefel C; Sia KC; Newman JP; Mohamed-Bashir SA; Ng WH; Lam PY
Br J Cancer; 2014 Jan; 110(1):94-106. PubMed ID: 24196790
[TBL] [Abstract][Full Text] [Related]
25. HSV1716 persistence in primary human glioma cells in vitro.
Harland J; Papanastassiou V; Brown SM
Gene Ther; 2002 Sep; 9(17):1194-8. PubMed ID: 12170384
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
29. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy.
Boyd M; Mairs SC; Stevenson K; Livingstone A; Clark AM; Ross SC; Mairs RJ
J Gene Med; 2002; 4(5):567-76. PubMed ID: 12221650
[TBL] [Abstract][Full Text] [Related]
30. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
31. Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.
Brader P; Kelly KJ; Chen N; Yu YA; Zhang Q; Zanzonico P; Burnazi EM; Ghani RE; Serganova I; Hricak H; Szalay AA; Fong Y; Blasberg RG
Clin Cancer Res; 2009 Jun; 15(11):3791-801. PubMed ID: 19470726
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.
Shah AC; Benos D; Gillespie GY; Markert JM
J Neurooncol; 2003 Dec; 65(3):203-26. PubMed ID: 14682372
[TBL] [Abstract][Full Text] [Related]
33. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
34. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
Kostova Y; Mantwill K; Holm PS; Anton M
Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
[TBL] [Abstract][Full Text] [Related]
35. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.
Herrlinger U; Jacobs A; Quinones A; Woiciechowsky C; Sena-Esteves M; Rainov NG; Fraefel C; Breakefield XO
Hum Gene Ther; 2000 Jul; 11(10):1429-38. PubMed ID: 10910140
[TBL] [Abstract][Full Text] [Related]
36. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
Kanai R; Tomita H; Shinoda A; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
Gene Ther; 2006 Jan; 13(2):106-16. PubMed ID: 16163378
[TBL] [Abstract][Full Text] [Related]
37. Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
McCluskey AG; Boyd M; Pimlott SL; Babich JW; Gaze MN; Mairs RJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S28-35. PubMed ID: 18819996
[TBL] [Abstract][Full Text] [Related]
38. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
Friedman GK; Langford CP; Coleman JM; Cassady KA; Parker JN; Markert JM; Yancey Gillespie G
J Neurooncol; 2009 Nov; 95(2):199-209. PubMed ID: 19521665
[TBL] [Abstract][Full Text] [Related]
39. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
40. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]